Coherus Biosciences | CHRS - Net Income


Coherus Biosciences reported $-56.57M in Net Income for its fiscal quarter ending in March of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -7.74M 6.4M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Baxter International USD -1.13B 1.08B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Coherus Biosciences USD -56.57M 5.87M Mar/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Fujifilm JPY 72.66B 6.27B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Merck USD 2.96B 2.82B Dec/2025
Myriad Genetics USD -27.4M 303.1M Sep/2025
Pacira USD 1.64M 3.8M Dec/2025
Perrigo USD -1.42B 1.43B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Teva Pharmaceutical Industries USD 480M 47M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xencor USD -6.65M 626K Dec/2025
Zoetis USD 603M 118M Dec/2025